Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00348894 · ClinicalTrials.gov registry record · Phase 2
[S,S]-Reboxetine Long Term Safety Study In Chronic Painful Diabetic Peripheral Neuropathy.
A Phase 2 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
NCT00348894 is a Phase 2 study that was terminated before completion, run by Pfizer. The registered enrollment target is 136 participants.
The verdict
NCT00348894, a Phase 2 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the long-term safety and tolerability of \[S,S\]-Reboxetine in patients with chronic painful diabetic peripheral neuropathy
Interventions
- DRUG [S,S]-Reboxetine
- DRUG Any
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2006-07 |
| Est. Completion | 2007-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00348894
The ClinicalTrials.gov registry entry for NCT00348894 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which [S,S]-Reboxetine is the first listed.
NCT00348894 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00348894 about?
NCT00348894 is a clinical study titled "[S,S]-Reboxetine Long Term Safety Study In Chronic Painful Diabetic Peripheral Neuropathy.". The purpose of this study is to assess the long-term safety and tolerability of \[S,S\]-Reboxetine in patients with chronic painful diabetic peripheral neuropathy
What is the current status of trial NCT00348894?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2006-07. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00348894?
The interventions under investigation include: [S,S]-Reboxetine (DRUG), Any (DRUG).
Who is sponsoring clinical trial NCT00348894?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.